These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 21905086

  • 21. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C.
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [Abstract] [Full Text] [Related]

  • 23. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
    Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S.
    J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ, Borgstein NG, Ellsworth P, Djurhuus JC.
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [Abstract] [Full Text] [Related]

  • 28. Variability of urodynamic parameters in patients with overactive bladder.
    Frenkl TL, Railkar R, Palcza J, Scott BB, Alon A, Green S, Schaefer W.
    Neurourol Urodyn; 2011 Nov; 30(8):1565-9. PubMed ID: 21674594
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P, Kaplan S, De Koning Gans HJ, Millard R.
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z.
    Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [Abstract] [Full Text] [Related]

  • 33. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N.
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [Abstract] [Full Text] [Related]

  • 34. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
    Liu HT, Chancellor MB, Kuo HC.
    BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
    [Abstract] [Full Text] [Related]

  • 35. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS, Doo CK, Lee KS.
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [Abstract] [Full Text] [Related]

  • 36. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
    Peeker R, Samsioe G, Kowalski J, Andersson AS, Bergqvist A.
    Scand J Urol Nephrol; 2010 Apr; 44(3):138-46. PubMed ID: 20367449
    [Abstract] [Full Text] [Related]

  • 37. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB, Jumadilova Z, Carlsson M.
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [Abstract] [Full Text] [Related]

  • 38. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
    Chapple CR, Abrams P, Andersson KE, Radziszewski P, Masuda T, Small M, Kuwayama T, Deacon S.
    J Urol; 2014 Jan; 191(1):253-60. PubMed ID: 24018240
    [Abstract] [Full Text] [Related]

  • 39. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC, McDonnell DD, Chen A, Wan GJ.
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [Abstract] [Full Text] [Related]

  • 40. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
    Kelleher CJ, Reese PR, Pleil AM, Okano GJ.
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S608-15. PubMed ID: 12516955
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.